HL
Hongbo Lu (Director) filed 3 Form 4 reports in the trailing twelve months (2 purchases, 1 sale), most often in Zenas BioPharma, Inc. (ZBIO). Across 2 priced purchase filings, the average 21-session return was +4.8% from execution and -7.6% from disclosure (delay-adjusted; derived). The largest single filing was $1.5M of ZBIO (75,000 sh × $20.00, as filed), executed Mar 31. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+4.8%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-7.6%
same 2 filings, from disclosure
Filings, ttm
3
2 buys · 1 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.3M
shares × price, as filed
Last traded
May 12
Filed May 14
Median ADV $181.7M across their filed names
Open performance→Volume by month
Buys $8.1M
Sells $228K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
ZBIORecent filings
ARWRSALE
Arrowhead Pharmaceuticals, Inc.
View filing →
$228K2,970 sh × $76.88
Exec May 12
Filed May 14 · 5:30 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $1.5M
75,000 sh × $20.00
Exec Mar 31
Filed Mar 31 · 5:00 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $585K
25,985 sh × $22.50
Exec Feb 11
Filed Feb 13 · 5:35 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $6.0M
321,983 sh across 2 lots
Exec Sep 13 2024
Filed Oct 9 2025 · 3:37 PM ET †